Alaunos Therapeutics Inc. (TCRT)
TCRT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1107421/000119312526134720/0001193125-26-134720-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | TCRT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001107421 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $5K |
| Net income | -$4.2M |
| Operating income | -$4.2M |
| Net margin | -83520.0% |
| Operating margin | -84500.0% |
| Revenue growth | -50.0% |
| Cash | $1.4M |
| Total assets | $3.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1346.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Based on the current cash forecast and the Company's dependence on its ability to obtain additional financing to fund its operations after the current resources are exhausted, about which there can be no certainty, management has determined that the Company's present capital resources will not be sufficient to fund its planned operations for at least one year from the issuance date of the financial statements which r" | 10-Q 2026-08-14 |
| Cash and burn | $124K cash; operating cash flow -$682K a quarter. | Report 2026-06-30 |
| Shares outstanding | 2,540,480 (2026-08-14); 2,194,941 a year earlier; 240,627,055 three years earlier. 3y figure adjusted for splits (1-for-150 overall). | Cover page 2026-08-14 |
| Reverse splits, 3 years | 2; latest 1-for-10 on 2024-07-18 | Source 2024-07-18 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-11-13 |
| Exchange deficiency notices, 12 months | 2 (8-K item 3.01) | 8-K 2026-10-09 |
| Auditor | Cherry Bekaert LLP, Tampa, Florida, United States | PCAOB Form AP 2026-04-01 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
| Market cap check | The listing's market cap implies 4,128,460 shares at the 2026-11-13 price; the latest SEC cover count is 2,540,480 as of 2026-08-14. One of the two share counts is stale. | Nasdaq screener and SEC cover page |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $0 | -$952K | -$300K | $124K | No debt tags | $3K | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | $0 | -$1.0M | -$1.0M | $354K | No debt tags | $3K | 10-Q 2026-05-15 |
| Q4 2025 2025-12-31 | $3K | -$893K | -$552K | $1.4M | No debt tags | $5K | 10-K 2026-03-31 |
| Q3 2025 2025-09-30 | $0 | -$1.2M | -$844K | $1.9M | No debt tags | $6K | 10-Q 2025-11-14 |
| Q2 2025 2025-06-30 | $0 | -$1.1M | -$701K | $2.9M | No debt tags | $6K | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | $2K | -$1.1M | -$772K | $319K | No debt tags | $10K | 10-Q 2026-05-15 |
| Q4 2024 2024-12-31 | $4K | -$742K | -$592K | $1.1M | $0 | $9K | 10-K 2026-03-31 |
| Q3 2024 2024-09-30 | $0 | -$1.1M | -$781K | $1.7M | No debt tags | $6K | 10-Q 2025-11-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-11-13 |
| Latest annual report | 10-K/A | 2026-04-30 |
| Latest quarterly / interim | 10-Q | 2026-11-16 |
| Latest current report | 8-K | 2026-10-23 |
| Latest proxy | PRE 14A | 2026-11-13 |
Source: SEC EDGAR submissions feed, 1,003 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -6.3% |
| 1 month | -46.2% |
| 3 months | -18.1% |
| Year to date | -49.5% |
| 1 year | -42.8% |
| From 52-week high | -62.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| SNGX | Soligenix Inc. | $0.2882 | -10.22% | $6.7M |
| TPST | Tempest Therapeutics Inc. | $0.3418 | -10.50% | $6.8M |
| ADXN | Addex Therapeutics Ltd | $3.83 | -5.67% | $6.5M |
| XCUR | Exicure Inc. | $1.07 | -0.93% | $7.0M |
| ENVB | Enveric Biosciences Inc. | $1.44 | -4.95% | $6.4M |
| TOVX | Theriva Biologics Inc. | $0.1400 | -2.85% | $6.4M |
| LGVN | Longeveron Inc. | $2.14 | -14.06% | $7.2M |
| IMRN | Immuron Limited | $0.8996 | +2.23% | $7.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier